Naylor Stuart 4
4 · MeiraGTx Holdings plc · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
MeiraGTx (MGTX) Chief Scientific Officer Stuart Naylor Receives Award
What Happened
- Stuart Naylor, Chief Scientific Officer, Ophthalmology at MeiraGTx Holdings plc, received a grant of 70,000 restricted share units (RSUs) on 2026-06-25. The reported acquisition price is $0.00 per unit — this is an equity award (transaction code A), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-25; Filing date: 2026-06-29 (filed within required reporting window).
- Award amount: 70,000 RSUs; reported price: $0.00 (derivative award).
- Shares owned after transaction: not specified in the filing excerpt.
- Footnotes: F1 — each RSU converts into one ordinary share upon vesting. F2 — vesting schedule: 50% on the 2nd anniversary of the grant date, 25% on the 3rd anniversary, and 25% on the 4th anniversary.
- No indication in the filing of tax withholding, 10b5-1 plan, or immediate sale of shares.
Context
- This is a routine equity compensation grant to an executive and does not reflect an open-market buy or sell. RSUs have no immediate cash value until they vest and convert into shares; vesting timing determines when the insider will actually receive tradable stock.
Insider Transaction Report
Form 4
Naylor Stuart
CHIEF SCI OFCR, OPHTHALMOLOGY
Transactions
- Award
Restricted Share Units
[F1][F2]2026-06-25+70,000→ 70,000 total→ Ordinary Shares (70,000 underlying)
Footnotes (2)
- [F1]Each restricted share unit converts into one ordinary share upon vesting.
- [F2]Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date.
Signature
/s/ Richard Giroux, Attorney-in-Fact for Stuart Naylor|2026-06-29